APO Research
Talk to an analyst

APO RESEARCH · REPORT

Pulmonary Arterial Hypertension Treatment

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Pulmonary Arterial Hypertension Treatment Industry Growth and Trends Forecast to 2032

20 December 202587 pages

Choose your research edition.

Industry ResearchPulmonary Arterial Hypertension Treatment Industry Research Report 2026111 pages · $2,950 USDIndustry Growth & TrendsGlobal Pulmonary Arterial Hypertension Treatment Industry Growth and Trends Forecast to 203287 pages · $3,450 USDMarket StructureGlobal Pulmonary Arterial Hypertension Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032181 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pulmonary Arterial Hypertension Treatment Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Pulmonary Arterial Hypertension Treatment Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

According to APO Research, the global Pulmonary Arterial Hypertension Treatment market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Pulmonary Arterial Hypertension Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Pulmonary Arterial Hypertension Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Pulmonary Arterial Hypertension Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global companies in the Pulmonary Arterial Hypertension Treatment market include GSK, Teva Pharmaceuticals Inc, Eli Lilly and Company, Pfizer Inc, Bayer AG, United Therapeutic Corporation, SteadyMed Ltd, Gilead Sciences, Inc and Actelion Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Pulmonary Arterial Hypertension Treatment market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Pulmonary Arterial Hypertension Treatment market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Pulmonary Arterial Hypertension Treatment market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Pulmonary Arterial Hypertension Treatment.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading companies in the global Pulmonary Arterial Hypertension Treatment market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Pulmonary Arterial Hypertension Treatment Market by Company

GSK

Teva Pharmaceuticals Inc

Eli Lilly and Company

Pfizer Inc

Bayer AG

United Therapeutic Corporation

SteadyMed Ltd

Gilead Sciences, Inc

Actelion Inc

Pulmonary Arterial Hypertension Treatment Segment by Type

Vasodilators

Endothelin Receptor Antagonists (ERA)

Phosphodiesterase 5 (PDE 5) Inhibitors

Soluble Guanylate Cyclase (SGC) Stimulator

Pulmonary Arterial Hypertension Treatment Segment by Application

Hospital Pharmacies

Online Pharmacies

Retail Pharmacies

Pulmonary Arterial Hypertension Treatment Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pulmonary Arterial Hypertension Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pulmonary Arterial Hypertension Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pulmonary Arterial Hypertension Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 5: Detailed analysis of Pulmonary Arterial Hypertension Treatment companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.

Chapter 12: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Global Pulmonary Arterial Hypertension Treatment Market Size (US$ Million) Comparison by Region: 2021 VS 2025 VS 2032 Table 2. Global Pulmonary Arterial Hypertension Treatment Market Size by Region (2021-2026) & (US$ Million) Table 3. Global Pulmonary Arterial Hypertension Treatment Market Share by Region (2021-2026) Table 4. Global Pulmonary Arterial Hypertension Treatment Market Size by Region (2027-2032) & (US$ Million) Table 5. Global Pulmonary Arterial Hypertension Treatment Market Share by Region (2027-2032) Table 6. Global Pulmonary Arterial Hypertension Treatment Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Pulmonary Arterial Hypertension Treatment Market Size by Type (2021-2026) & (US$ Million) Table 8. Global Pulmonary Arterial Hypertension Treatment Market Size Share by Type (2021-2026) Table 9. Global Pulmonary Arterial Hypertension Treatment Market Size Forecasted by Type (2027-2032) & (US$ Million) Table 10. Global Pulmonary Arterial Hypertension Treatment Market Size Share Forecasted by Type (2027-2032) Table 11. North America Pulmonary Arterial Hypertension Treatment Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 12. North America Pulmonary Arterial Hypertension Treatment Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 13. Europe Pulmonary Arterial Hypertension Treatment Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 14. Europe Pulmonary Arterial Hypertension Treatment Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 15. Asia-Pacific Pulmonary Arterial Hypertension Treatment Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 16. Asia-Pacific Pulmonary Arterial Hypertension Treatment Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 17. Latin America Pulmonary Arterial Hypertension Treatment Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 18. Latin America Pulmonary Arterial Hypertension Treatment Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 19. Middle East and Africa Pulmonary Arterial Hypertension Treatment Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 20. Middle East and Africa Pulmonary Arterial Hypertension Treatment Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 21. Global Pulmonary Arterial Hypertension Treatment Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 22. Global Pulmonary Arterial Hypertension Treatment Market Size by Application (2021-2026) & (US$ Million) Table 23. Global Pulmonary Arterial Hypertension Treatment Market Size Share by Application (2021-2026) Table 24. Global Pulmonary Arterial Hypertension Treatment Market Size Forecasted by Application (2027-2032) & (US$ Million) Table 25. Global Pulmonary Arterial Hypertension Treatment Market Size Share Forecasted by Application (2027-2032) Table 26. North America Pulmonary Arterial Hypertension Treatment Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 27. North America Pulmonary Arterial Hypertension Treatment Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 28. Europe Pulmonary Arterial Hypertension Treatment Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 29. Europe Pulmonary Arterial Hypertension Treatment Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 30. Asia-Pacific Pulmonary Arterial Hypertension Treatment Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 31. Asia-Pacific Pulmonary Arterial Hypertension Treatment Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 32. Latin America Pulmonary Arterial Hypertension Treatment Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 33. Latin America Pulmonary Arterial Hypertension Treatment Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 34. Middle East and Africa Pulmonary Arterial Hypertension Treatment Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 35. Middle East and Africa Pulmonary Arterial Hypertension Treatment Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 36. Pulmonary Arterial Hypertension Treatment Industry Trends Table 37. Pulmonary Arterial Hypertension Treatment Industry Drivers Table 38. Pulmonary Arterial Hypertension Treatment Industry Opportunities and Challenges Table 39. Pulmonary Arterial Hypertension Treatment Industry Restraints Table 40. Global Pulmonary Arterial Hypertension Treatment Revenue by Company (US$ Million) & (2021-2026) Table 41. Global Pulmonary Arterial Hypertension Treatment Revenue Market Share by Company (2021-2026) Table 42. Global Pulmonary Arterial Hypertension Treatment Industry Company Ranking, 2024 VS 2025 VS 2026 Table 43. Global Pulmonary Arterial Hypertension Treatment Key Company Headquarters & Area Served Table 44. Global Pulmonary Arterial Hypertension Treatment Company, Product Type & Application Table 45. Global Pulmonary Arterial Hypertension Treatment Company Commercialization Time Table 46. Global Company Market Concentration Ratio (CR5 and HHI) Table 47. Global Pulmonary Arterial Hypertension Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 48. GSK Company Information Table 49. GSK Business Overview Table 50. GSK Pulmonary Arterial Hypertension Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 51. GSK Pulmonary Arterial Hypertension Treatment Product Portfolio Table 52. GSK Recent Development Table 53. Teva Pharmaceuticals Inc Company Information Table 54. Teva Pharmaceuticals Inc Business Overview Table 55. Teva Pharmaceuticals Inc Pulmonary Arterial Hypertension Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 56. Teva Pharmaceuticals Inc Pulmonary Arterial Hypertension Treatment Product Portfolio Table 57. Teva Pharmaceuticals Inc Recent Development Table 58. Eli Lilly and Company Company Information Table 59. Eli Lilly and Company Business Overview Table 60. Eli Lilly and Company Pulmonary Arterial Hypertension Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 61. Eli Lilly and Company Pulmonary Arterial Hypertension Treatment Product Portfolio Table 62. Eli Lilly and Company Recent Development Table 63. Pfizer Inc Company Information Table 64. Pfizer Inc Business Overview Table 65. Pfizer Inc Pulmonary Arterial Hypertension Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 66. Pfizer Inc Pulmonary Arterial Hypertension Treatment Product Portfolio Table 67. Pfizer Inc Recent Development Table 68. Bayer AG Company Information Table 69. Bayer AG Business Overview Table 70. Bayer AG Pulmonary Arterial Hypertension Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 71. Bayer AG Pulmonary Arterial Hypertension Treatment Product Portfolio Table 72. Bayer AG Recent Development Table 73. United Therapeutic Corporation Company Information Table 74. United Therapeutic Corporation Business Overview Table 75. United Therapeutic Corporation Pulmonary Arterial Hypertension Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 76. United Therapeutic Corporation Pulmonary Arterial Hypertension Treatment Product Portfolio Table 77. United Therapeutic Corporation Recent Development Table 78. SteadyMed Ltd Company Information Table 79. SteadyMed Ltd Business Overview Table 80. SteadyMed Ltd Pulmonary Arterial Hypertension Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 81. SteadyMed Ltd Pulmonary Arterial Hypertension Treatment Product Portfolio Table 82. SteadyMed Ltd Recent Development Table 83. Gilead Sciences, Inc Company Information Table 84. Gilead Sciences, Inc Business Overview Table 85. Gilead Sciences, Inc Pulmonary Arterial Hypertension Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 86. Gilead Sciences, Inc Pulmonary Arterial Hypertension Treatment Product Portfolio Table 87. Gilead Sciences, Inc Recent Development Table 88. Actelion Inc Company Information Table 89. Actelion Inc Business Overview Table 90. Actelion Inc Pulmonary Arterial Hypertension Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 91. Actelion Inc Pulmonary Arterial Hypertension Treatment Product Portfolio Table 92. Actelion Inc Recent Development Table 93. North America Pulmonary Arterial Hypertension Treatment Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 94. North America Pulmonary Arterial Hypertension Treatment Market Size by Country (2021-2026) & (US$ Million) Table 95. North America Pulmonary Arterial Hypertension Treatment Market Share by Country (2021-2026) Table 96. North America Pulmonary Arterial Hypertension Treatment Market Size Forecast by Country (2027-2032) & (US$ Million) Table 97. North America Pulmonary Arterial Hypertension Treatment Market Share Forecast by Country (2027-2032) Table 98. Europe Pulmonary Arterial Hypertension Treatment Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 99. Europe Pulmonary Arterial Hypertension Treatment Market Size by Country (2021-2026) & (US$ Million) Table 100. Europe Pulmonary Arterial Hypertension Treatment Market Share by Country (2021-2026) Table 101. Europe Pulmonary Arterial Hypertension Treatment Market Size Forecast by Country (2027-2032) & (US$ Million) Table 102. Europe Pulmonary Arterial Hypertension Treatment Market Share Forecast by Country (2027-2032) Table 103. Asia-Pacific Pulmonary Arterial Hypertension Treatment Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 104. Asia-Pacific Pulmonary Arterial Hypertension Treatment Market Size by Country (2021-2026) & (US$ Million) Table 105. Asia-Pacific Pulmonary Arterial Hypertension Treatment Market Share by Country (2021-2026) Table 106. Asia-Pacific Pulmonary Arterial Hypertension Treatment Market Size Forecast by Country (2027-2032) & (US$ Million) Table 107. Asia-Pacific Pulmonary Arterial Hypertension Treatment Market Share Forecast by Country (2027-2032) Table 108. Latin America Pulmonary Arterial Hypertension Treatment Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 109. Latin America Pulmonary Arterial Hypertension Treatment Market Size by Country (2021-2026) & (US$ Million) Table 110. Latin America Pulmonary Arterial Hypertension Treatment Market Share by Country (2021-2026) Table 111. Latin America Pulmonary Arterial Hypertension Treatment Market Size Forecast by Country (2027-2032) & (US$ Million) Table 112. Latin America Pulmonary Arterial Hypertension Treatment Market Share Forecast by Country (2027-2032) Table 113. Middle East & Africa Pulmonary Arterial Hypertension Treatment Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 114. Middle East & Africa Pulmonary Arterial Hypertension Treatment Market Size by Country (2021-2026) & (US$ Million) Table 115. Middle East & Africa Pulmonary Arterial Hypertension Treatment Market Share by Country (2021-2026) Table 116. Middle East & Africa Pulmonary Arterial Hypertension Treatment Market Size Forecast by Country (2027-2032) & (US$ Million) Table 117. Middle East & Africa Pulmonary Arterial Hypertension Treatment Market Share Forecast by Country (2027-2032) Table 118. Research Programs/Design for This Report Table 119. Authors List of This Report Table 120. Secondary Sources List of Figures Figure 1.List of Figures Figure 2. Pulmonary Arterial Hypertension Treatment Product Image Figure 3. Global Pulmonary Arterial Hypertension Treatment Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 4. Global Pulmonary Arterial Hypertension Treatment Market Size (2021-2032) & (US$ Million) Figure 5. Global Pulmonary Arterial Hypertension Treatment Market Share by Region: 2025 VS 2032 Figure 6. Global Pulmonary Arterial Hypertension Treatment Market Share by Region (2021-2032) Figure 7. North America Pulmonary Arterial Hypertension Treatment Market Size Growth Rate (2021-2032) & (US$ Million) Figure 8. Europe Pulmonary Arterial Hypertension Treatment Market Size Growth Rate (2021-2032) & (US$ Million) Figure 9. Asia-Pacific Pulmonary Arterial Hypertension Treatment Market Size Growth Rate (2021-2032) & (US$ Million) Figure 10. Latin America Pulmonary Arterial Hypertension Treatment Market Size Growth Rate (2021-2032) & (US$ Million) Figure 11. Middle East & Africa Pulmonary Arterial Hypertension Treatment Market Size Growth Rate (2021-2032) & (US$ Million) Figure 12. Vasodilators Image Figure 13. Global Vasodilators Market Size YoY Growth (2021-2032) & (US$ Million) Figure 14. Endothelin Receptor Antagonists (ERA) Image Figure 15. Global Endothelin Receptor Antagonists (ERA) Market Size YoY Growth (2021-2032) & (US$ Million) Figure 16. Phosphodiesterase 5 (PDE 5) Inhibitors Image Figure 17. Global Phosphodiesterase 5 (PDE 5) Inhibitors Market Size YoY Growth (2021-2032) & (US$ Million) Figure 18. Soluble Guanylate Cyclase (SGC) Stimulator Image Figure 19. Global Soluble Guanylate Cyclase (SGC) Stimulator Market Size YoY Growth (2021-2032) & (US$ Million) Figure 20. Global Pulmonary Arterial Hypertension Treatment Market Size Overview by Type (2021-2032) & (US$ Million) Figure 21. Global Pulmonary Arterial Hypertension Treatment Market Share by Type 2025 VS 2032 Figure 22. North America Pulmonary Arterial Hypertension Treatment Market Size Share by Type (2021-2032) Figure 23. Europe Pulmonary Arterial Hypertension Treatment Market Size Share by Type (2021-2032) Figure 24. Asia-Pacific Pulmonary Arterial Hypertension Treatment Market Size Share by Type (2021-2032) Figure 25. Latin America Pulmonary Arterial Hypertension Treatment Market Size Share by Type (2021-2032) Figure 26. Middle East and Africa Pulmonary Arterial Hypertension Treatment Market Size Share by Type (2021-2032) Figure 27. Hospital Pharmacies Image Figure 28. Global Hospital Pharmacies Market Size YoY Growth (2021-2032) & (US$ Million) Figure 29. Online Pharmacies Image Figure 30. Global Online Pharmacies Market Size YoY Growth (2021-2032) & (US$ Million) Figure 31. Retail Pharmacies Image Figure 32. Global Retail Pharmacies Market Size YoY Growth (2021-2032) & (US$ Million) Figure 33. Global Pulmonary Arterial Hypertension Treatment Market Size Overview by Application (2021-2032) & (US$ Million) Figure 34. Global Pulmonary Arterial Hypertension Treatment Market Share by Application 2025 VS 2032 Figure 35. North America Pulmonary Arterial Hypertension Treatment Market Size Share by Application (2021-2032) Figure 36. Europe Pulmonary Arterial Hypertension Treatment Market Size Share by Application (2021-2032) Figure 37. Asia-Pacific Pulmonary Arterial Hypertension Treatment Market Size Share by Application (2021-2032) Figure 38. Latin America Pulmonary Arterial Hypertension Treatment Market Size Share by Application (2021-2032) Figure 39. Middle East and Africa Pulmonary Arterial Hypertension Treatment Market Size Share by Application (2021-2032) Figure 40. Global Top 5 and 10 Pulmonary Arterial Hypertension Treatment Players Market Share by Revenue in 2025 Figure 41. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 42. North America Pulmonary Arterial Hypertension Treatment Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 43. North America Pulmonary Arterial Hypertension Treatment Market Share by Country: 2021 VS 2025 VS 2032 Figure 44. North America Pulmonary Arterial Hypertension Treatment Market Share by Country (2021-2032) Figure 45. Europe Pulmonary Arterial Hypertension Treatment Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 46. Europe Pulmonary Arterial Hypertension Treatment Market Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Pulmonary Arterial Hypertension Treatment Market Share by Country (2021-2032) Figure 48. Asia-Pacific Pulmonary Arterial Hypertension Treatment Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 49. Asia-Pacific Pulmonary Arterial Hypertension Treatment Market Share by Country: 2021 VS 2025 VS 2032 Figure 50. Asia-Pacific Pulmonary Arterial Hypertension Treatment Market Share by Country (2021-2032) Figure 51. Latin America Pulmonary Arterial Hypertension Treatment Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Latin America Pulmonary Arterial Hypertension Treatment Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Latin America Pulmonary Arterial Hypertension Treatment Market Share by Country (2021-2032) Figure 54. Middle East & Africa Pulmonary Arterial Hypertension Treatment Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 55. Middle East & Africa Pulmonary Arterial Hypertension Treatment Market Share by Country: 2021 VS 2025 VS 2032 Figure 56. Middle East & Africa Pulmonary Arterial Hypertension Treatment Market Share by Country (2021-2032) Figure 57. Years Considered Figure 58. Research Process Figure 59. Key Executives Interviewed

Scope & coverage.

Types
  • Vasodilators
  • Endothelin Receptor Antagonists (ERA)
  • Phosphodiesterase 5 (PDE 5) Inhibitors
  • Soluble Guanylate Cyclase (SGC) Stimulator
Applications
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
Companies covered
  • GSK
  • Teva Pharmaceuticals Inc
  • Eli Lilly and Company
  • Pfizer Inc
  • Bayer AG
  • United Therapeutic Corporation
  • SteadyMed Ltd
  • Gilead Sciences, Inc
  • Actelion Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.3 Global Pulmonary Arterial Hypertension Treatment Market Size Overview by Region 2021 VS 2025 VS 2032
  4. 1.4 Global Pulmonary Arterial Hypertension Treatment Market Size by Region (2021-2032)
  5. 1.4.1 Global Pulmonary Arterial Hypertension Treatment Market Size by Region (2021-2026)
  6. 1.4.2 Global Pulmonary Arterial Hypertension Treatment Market Size by Region (2027-2032)
  7. 1.5 Key Regions Pulmonary Arterial Hypertension Treatment Market Size (2021-2032)
  8. 1.5.1 North America Pulmonary Arterial Hypertension Treatment Market Size Growth Rate (2021-2032)
  9. 1.5.2 Europe Pulmonary Arterial Hypertension Treatment Market Size Growth Rate (2021-2032)
  10. 1.5.3 Asia-Pacific Pulmonary Arterial Hypertension Treatment Market Size Growth Rate (2021-2032)
  11. 1.5.4 South America Pulmonary Arterial Hypertension Treatment Market Size Growth Rate (2021-2032)
  12. 1.5.5 Middle East & Africa Pulmonary Arterial Hypertension Treatment Market Size Growth Rate (2021-2032)
2 Pulmonary Arterial Hypertension Treatment Market by Type
  1. 2.1 Type Introduction
  2. 2.1.1 Vasodilators
  3. 2.1.2 Endothelin Receptor Antagonists (ERA)
  4. 2.1.3 Phosphodiesterase 5 (PDE 5) Inhibitors
  5. 2.1.4 Soluble Guanylate Cyclase (SGC) Stimulator
  6. 2.2 Global Pulmonary Arterial Hypertension Treatment Market Size by Type
  7. 2.2.1 Global Pulmonary Arterial Hypertension Treatment Market Size Overview by Type (2021-2032)
  8. 2.2.2 Global Pulmonary Arterial Hypertension Treatment Historic Market Size Review by Type (2021-2026)
  9. 2.2.3 Global Pulmonary Arterial Hypertension Treatment Market Size Forecasted by Type (2027-2032)
  10. 2.3 Global Pulmonary Arterial Hypertension Treatment Market Size by Regions
  11. 2.3.1 North America Pulmonary Arterial Hypertension Treatment Market Size Breakdown by Type (2021-2026)
  12. 2.3.2 Europe Pulmonary Arterial Hypertension Treatment Market Size Breakdown by Type (2021-2026)
  13. 2.3.3 Asia-Pacific Pulmonary Arterial Hypertension Treatment Market Size Breakdown by Type (2021-2026)
  14. 2.3.4 South America Pulmonary Arterial Hypertension Treatment Market Size Breakdown by Type (2021-2026)
  15. 2.3.5 Middle East and Africa Pulmonary Arterial Hypertension Treatment Market Size Breakdown by Type (2021-2026)
3 Pulmonary Arterial Hypertension Treatment Market by Application
  1. 3.1 Type Introduction
  2. 3.1.1 Hospital Pharmacies
  3. 3.1.2 Online Pharmacies
  4. 3.1.3 Retail Pharmacies
  5. 3.2 Global Pulmonary Arterial Hypertension Treatment Market Size by Application
  6. 3.2.1 Global Pulmonary Arterial Hypertension Treatment Market Size Overview by Application (2021-2032)
  7. 3.2.2 Global Pulmonary Arterial Hypertension Treatment Historic Market Size Review by Application (2021-2026)
  8. 3.2.3 Global Pulmonary Arterial Hypertension Treatment Market Size Forecasted by Application (2027-2032)
  9. 3.3 Global Pulmonary Arterial Hypertension Treatment Market Size by Regions
  10. 3.3.1 North America Pulmonary Arterial Hypertension Treatment Market Size Breakdown by Application (2021-2026)
  11. 3.3.2 Europe Pulmonary Arterial Hypertension Treatment Market Size Breakdown by Application (2021-2026)
  12. 3.3.3 Asia-Pacific Pulmonary Arterial Hypertension Treatment Market Size Breakdown by Application (2021-2026)
  13. 3.3.4 South America Pulmonary Arterial Hypertension Treatment Market Size Breakdown by Application (2021-2026)
  14. 3.3.5 Middle East and Africa Pulmonary Arterial Hypertension Treatment Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
  1. 4.1 Pulmonary Arterial Hypertension Treatment Industry Trends
  2. 4.2 Pulmonary Arterial Hypertension Treatment Industry Drivers
  3. 4.3 Pulmonary Arterial Hypertension Treatment Industry Opportunities and Challenges
  4. 4.4 Pulmonary Arterial Hypertension Treatment Industry Restraints
5 Competitive Insights by Company
  1. 5.1 Global Top Players by Pulmonary Arterial Hypertension Treatment Revenue (2021-2026)
  2. 5.2 Global Pulmonary Arterial Hypertension Treatment Industry Company Ranking, 2024 VS 2025 VS 2026
  3. 5.3 Global Pulmonary Arterial Hypertension Treatment Key Company Headquarters & Area Served
  4. 5.4 Global Pulmonary Arterial Hypertension Treatment Company, Product Type & Application
  5. 5.5 Global Pulmonary Arterial Hypertension Treatment Company Commercialization Time
  6. 5.6 Market Competitive Analysis
  7. 5.6.1 Global Pulmonary Arterial Hypertension Treatment Market CR5 and HHI
  8. 5.6.2 Global Top 5 and 10 Pulmonary Arterial Hypertension Treatment Players Market Share by Revenue in 2025
  9. 5.6.3 2025 Pulmonary Arterial Hypertension Treatment Tier 1, Tier 2, and Tier 3
6 Company Profiles
  1. 6.1 GSK
  2. 6.1.1 GSK Company Information
  3. 6.1.2 GSK Business Overview
  4. 6.1.3 GSK Pulmonary Arterial Hypertension Treatment Revenue, Global Share and Gross Margin (2021-2026)
  5. 6.1.4 GSK Pulmonary Arterial Hypertension Treatment Product Portfolio
  6. 6.1.5 GSK Recent Developments
  7. 6.2 Teva Pharmaceuticals Inc
  8. 6.2.1 Teva Pharmaceuticals Inc Company Information
  9. 6.2.2 Teva Pharmaceuticals Inc Business Overview
  10. 6.2.3 Teva Pharmaceuticals Inc Pulmonary Arterial Hypertension Treatment Revenue, Global Share and Gross Margin (2021-2026)
  11. 6.2.4 Teva Pharmaceuticals Inc Pulmonary Arterial Hypertension Treatment Product Portfolio
  12. 6.2.5 Teva Pharmaceuticals Inc Recent Developments
  13. 6.3 Eli Lilly and Company
  14. 6.3.1 Eli Lilly and Company Company Information
  15. 6.3.2 Eli Lilly and Company Business Overview
  16. 6.3.3 Eli Lilly and Company Pulmonary Arterial Hypertension Treatment Revenue, Global Share and Gross Margin (2021-2026)
  17. 6.3.4 Eli Lilly and Company Pulmonary Arterial Hypertension Treatment Product Portfolio
  18. 6.3.5 Eli Lilly and Company Recent Developments
  19. 6.4 Pfizer Inc
  20. 6.4.1 Pfizer Inc Company Information
  21. 6.4.2 Pfizer Inc Business Overview
  22. 6.4.3 Pfizer Inc Pulmonary Arterial Hypertension Treatment Revenue, Global Share and Gross Margin (2021-2026)
  23. 6.4.4 Pfizer Inc Pulmonary Arterial Hypertension Treatment Product Portfolio
  24. 6.4.5 Pfizer Inc Recent Developments
  25. 6.5 Bayer AG
  26. 6.5.1 Bayer AG Company Information
  27. 6.5.2 Bayer AG Business Overview
  28. 6.5.3 Bayer AG Pulmonary Arterial Hypertension Treatment Revenue, Global Share and Gross Margin (2021-2026)
  29. 6.5.4 Bayer AG Pulmonary Arterial Hypertension Treatment Product Portfolio
  30. 6.5.5 Bayer AG Recent Developments
  31. 6.6 United Therapeutic Corporation
  32. 6.6.1 United Therapeutic Corporation Company Information
  33. 6.6.2 United Therapeutic Corporation Business Overview
  34. 6.6.3 United Therapeutic Corporation Pulmonary Arterial Hypertension Treatment Revenue, Global Share and Gross Margin (2021-2026)
  35. 6.6.4 United Therapeutic Corporation Pulmonary Arterial Hypertension Treatment Product Portfolio
  36. 6.6.5 United Therapeutic Corporation Recent Developments
  37. 6.7 SteadyMed Ltd
  38. 6.7.1 SteadyMed Ltd Company Information
  39. 6.7.2 SteadyMed Ltd Business Overview
  40. 6.7.3 SteadyMed Ltd Pulmonary Arterial Hypertension Treatment Revenue, Global Share and Gross Margin (2021-2026)
  41. 6.7.4 SteadyMed Ltd Pulmonary Arterial Hypertension Treatment Product Portfolio
  42. 6.7.5 SteadyMed Ltd Recent Developments
  43. 6.8 Gilead Sciences, Inc
  44. 6.8.1 Gilead Sciences, Inc Company Information
  45. 6.8.2 Gilead Sciences, Inc Business Overview
  46. 6.8.3 Gilead Sciences, Inc Pulmonary Arterial Hypertension Treatment Revenue, Global Share and Gross Margin (2021-2026)
  47. 6.8.4 Gilead Sciences, Inc Pulmonary Arterial Hypertension Treatment Product Portfolio
  48. 6.8.5 Gilead Sciences, Inc Recent Developments
  49. 6.9 Actelion Inc
  50. 6.9.1 Actelion Inc Company Information
  51. 6.9.2 Actelion Inc Business Overview
  52. 6.9.3 Actelion Inc Pulmonary Arterial Hypertension Treatment Revenue, Global Share and Gross Margin (2021-2026)
  53. 6.9.4 Actelion Inc Pulmonary Arterial Hypertension Treatment Product Portfolio
  54. 6.9.5 Actelion Inc Recent Developments
7 North America
  1. 7.1 North America Pulmonary Arterial Hypertension Treatment Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 7.2 North America Pulmonary Arterial Hypertension Treatment Market Size by Country (2021-2026)
  3. 7.3 North America Pulmonary Arterial Hypertension Treatment Market Size Forecast by Country (2027-2032)
8 Europe
  1. 8.1 Europe Pulmonary Arterial Hypertension Treatment Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 8.2 Europe Pulmonary Arterial Hypertension Treatment Market Size by Country (2021-2026)
  3. 8.3 Europe Pulmonary Arterial Hypertension Treatment Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
  1. 9.1 Asia-Pacific Pulmonary Arterial Hypertension Treatment Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 9.2 Asia-Pacific Pulmonary Arterial Hypertension Treatment Market Size by Country (2021-2026)
  3. 9.3 Asia-Pacific Pulmonary Arterial Hypertension Treatment Market Size Forecast by Country (2027-2032)
10 South America
  1. 10.1 South America Pulmonary Arterial Hypertension Treatment Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 10.2 South America Pulmonary Arterial Hypertension Treatment Market Size by Country (2021-2026)
  3. 10.3 South America Pulmonary Arterial Hypertension Treatment Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
  1. 11.1 Middle East & Africa Pulmonary Arterial Hypertension Treatment Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 11.2 Middle East & Africa Pulmonary Arterial Hypertension Treatment Market Size by Country (2021-2026)
  3. 11.3 Middle East & Africa Pulmonary Arterial Hypertension Treatment Market Size Forecast by Country (2027-2032)
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst